NccRCC 'material expansion opportunity' for Exelixis, says William Blair 07:10 EXEL, BMY After Exelixis (EXEL) announced initiation of the Phase III STELLAR-304 trial of zanzalintinib in combination with Bristol-Myers' (BMY) Opdivo in frontline advanced non-clear cell renal cell carcinoma, or nccRCC, William Blair analyst Andy Hsieh said he believes that the nccRCC market represents a "material expansion opportunity" for the zanzalintinib franchise. He estimates the global market in nccRCC "to be north of $1 billion commercially," added Hsieh, who has an Outperform rating on Exelixis shares.
So glad you guys nailed it! The ole' Choo Choo alert works*** Mirati Therapeutics, Inc. (MRTX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 43.45+2.14 (+5.18%) At close: December 22 04:00PM EST 44.76 +1.31 (+3.01%)<---------------- Pre-Market: 06:30AM EST
I got to walk around and clean up the yard. Check for more trees down. I have not seen the futures but I think we will go up today. This Lizard King he's back in my bed. Stinking of whiskey, boots still on. I told him-- you aint' going to get your usual hundred... he didn't listen.
Wow crazy winds. Bio Breakout! Up 5% on a down 300 day? Cytokinetics, Incorporated (CYTK) over 50 & 200 day-! NasdaqGS - NasdaqGS Real Time Price. 47.41+2.29 (+5.08%)<----------- At close: December 22 04:00PM EST 47.95 +0.54 (+1.14%) Pre-Market: 07:02AM EST
I'm just back at the wheels of steel. I took a hot bath and had Cramer on in the backround. I almst drowned myself on purpose. What a putz. He thought about it and blamed the retail trader.. he understands there is no interest in his show anymore and he realizes why nobody signed up for his morning investing club special.... He understands now that FANG stared all of this and that he himself is a major part of the hype and the heart of the problem. In short he looked in the mirror and didn't like what he saw. PUTZ
The Children Stoney! Quit instilling bad habits. $42.30 >>>Never chase a stock that dropped 50% overnight.